Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. COVID 19
  4. Back
  5. Board Wide
  6. Covid-19 Baricitinib for patients hospitalised due to COVID-19 (Adults and Children aged 2 years and older) (1040)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Covid-19 Baricitinib for patients hospitalised due to COVID-19 (Adults and Children aged 2 years and older) (1040)

Warning

Baricitinib is an anti-inflammatory treatment licensed for use in moderate to severe rheumatoid arthritis and moderate to severe atopic dermatitis, and has been studied in patients who are hospitalised due to COVID-19. It is a selective and reversible Janus kinase (JAK) 1 and 2 inhibitor. JAK-inhibitors are thought to control high levels of cytokines and inflammation, seen in patients with severe SARS-CoV-2 infection (Walz et al 2020).

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 12/06/2024

Next review date: 31/01/2027

Author(s): Samantha Carmichael, Beth White.

Version: 3

Author email(s): samantha.carmichael@ggc.scot.nhs.uk, beth.white@ggc.scot.nhs.uk.

Approved By: Covid 19 Tactical Group (Acute)

Reviewer name(s): Samantha Carmichael, Beth White.

Document Id: 1040